Skip to main content
S&P 5007,743.41+0.51%DOW51,828.62+0.93%NASDAQ27,068.72+0.48%BTC$83,896.00-0.86%ETH$2,687.00-0.12%GOLD$4,320.50+0.52%OIL$92.44-2.29%
Smart Investors Daily
PM

NASDAQ · PMN

ProMIS Neurosciences, Inc.

Healthcare · Biotechnology

$11.27

Down-$0.30 (-2.59%)

Updated Sep 26, 2026, 3:08 AM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
11.34M
P/E ratio
-0.41
Dividend yield
0.00%
52-week range
$6.27 – $27.40
Volume
20.1K
Avg. volume
31.52K

Price performance

PMN price history

1M range · 20 trading sessions · Daily adjusted prices

PMN closed at $11.57 after 20 trading sessions, down 17.30% for the selected period.

Last close
$11.57
Period change
-17.30%
Period low
$11.57
Period high
$14.37
Daily close
View OHLC price history
PMN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 24, 2026$12.83$13.06$11.29$11.5752.7K
Sep 23, 2026$13.45$13.7816$12.94$12.9443.69K
Sep 22, 2026$13.80$14.22$13.45$13.5894.2K
Sep 21, 2026$13.54$14.22$13.13$13.6326.24K
Sep 18, 2026$13.52$14.21$13.52$14.0124.47K
Sep 17, 2026$13.00$13.70$12.88$13.4622.78K
Sep 16, 2026$13.25$13.25$12.40$12.8833.29K
Sep 15, 2026$13.55$13.93$12.70$12.8949.09K
Sep 14, 2026$13.05$13.56$13.05$13.2621.79K
Sep 11, 2026$13.48$13.94$13.01$13.5619.95K
Sep 10, 2026$14.28$14.28$12.98$13.4054.09K
Sep 9, 2026$12.88$14.96$12.26$14.365126.79K
Sep 8, 2026$12.51$13.125$12.27$12.5338K
Sep 4, 2026$13.03$13.46$12.48$12.6024.09K
Sep 3, 2026$13.90$14.16$12.76$12.9037.39K
Sep 2, 2026$13.45$14.283$13.22$13.97589.67K
Sep 1, 2026$13.25$14.31$13.01$13.3542.37K
Aug 31, 2026$13.79$14.3429$13.07$13.0724.57K
Aug 28, 2026$14.07$14.60$13.47$13.78551.47K
Aug 27, 2026$14.62$15.19$13.92$13.9918.13K

Latest PMN news

The latest Smart Investors Daily articles mentioning PMN.

Stock researchCompany · Overview

PMN research

Overview

Company profile and research snapshot.

Company profile

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$18.00
Implied upside
—
Analysts
—
PMN recent ratings
DateFirmRatingTarget
Aug 14, 2026GuggenheimBuy—
Jul 29, 2026GuggenheimBuy—
Jul 28, 2026Chardan CapitalBuy—
Jul 27, 2026Chardan CapitalBuy—
Jul 8, 2026Roth CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 1, 2026

ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September

CAMBRIDGE, Mass, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming September 2026 conferences and key investor events, and will be available for one-on-one meetings. Conference details below: September 9-11: Cantor Global Healthcare ConferenceLocation: New York, NYFires

Benzinga · Aug 13, 2026

ProMIS Neurosciences Q2 EPS $(1.28) Beats $(1.38) Estimate

ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(1.28) per share which beat the analyst consensus estimate of $(1.38) by 7.25 percent. This is a 82.34 percent increase over losses of $(7.25) per share

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By